IT1247165B - Uso terapeutico della fosfatidilserina e derivati in patologie degenerative anche associate a disfunsioni immunitarie. - Google Patents

Uso terapeutico della fosfatidilserina e derivati in patologie degenerative anche associate a disfunsioni immunitarie.

Info

Publication number
IT1247165B
IT1247165B ITPD910055A ITPD910055A IT1247165B IT 1247165 B IT1247165 B IT 1247165B IT PD910055 A ITPD910055 A IT PD910055A IT PD910055 A ITPD910055 A IT PD910055A IT 1247165 B IT1247165 B IT 1247165B
Authority
IT
Italy
Prior art keywords
phosphatidylserine
therapeutic use
immunitary
dysfunctions
derivatives
Prior art date
Application number
ITPD910055A
Other languages
English (en)
Inventor
Valle Francesco Della
Aurelio Romeo
Giovanni Monastra
Original Assignee
Fidia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fidia Spa filed Critical Fidia Spa
Priority to ITPD910055A priority Critical patent/IT1247165B/it
Publication of ITPD910055A0 publication Critical patent/ITPD910055A0/it
Priority to EP92104039A priority patent/EP0505817A1/en
Priority to CA002063039A priority patent/CA2063039A1/en
Priority to JP4055015A priority patent/JPH05124978A/ja
Priority to KR1019920004186A priority patent/KR920017659A/ko
Publication of ITPD910055A1 publication Critical patent/ITPD910055A1/it
Application granted granted Critical
Publication of IT1247165B publication Critical patent/IT1247165B/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invenzione si riferisce ad un nuovo uso terapeutico della fosfatidilserina e di vari composti chimici ad essa affini in diverse patologie degenerative, anche associate a disfunzioni immunitarie, in cui è coinvolto il cosiddetto "tumor necrosis factor" (TNF).L'innovatività dell'applicazione in oggetto è di particolare rilevanza per la terapia farmacologica di patologie quali la sclerosi multipla (SM) e di diverse altre manifestazioni (fisiopatologiche) in cui è noto l'intervento del sopraddetto fattore.-
ITPD910055A 1991-03-15 1991-03-15 Uso terapeutico della fosfatidilserina e derivati in patologie degenerative anche associate a disfunsioni immunitarie. IT1247165B (it)

Priority Applications (5)

Application Number Priority Date Filing Date Title
ITPD910055A IT1247165B (it) 1991-03-15 1991-03-15 Uso terapeutico della fosfatidilserina e derivati in patologie degenerative anche associate a disfunsioni immunitarie.
EP92104039A EP0505817A1 (en) 1991-03-15 1992-03-10 Use of phosphatidylserine and its derivatives for the manufacture of a medicament for the treatment of degenerative pathologies also associated with immune disfunctions
CA002063039A CA2063039A1 (en) 1991-03-15 1992-03-13 Use of phosphatidylserine and its derivatives in degenerative pathologies also associated with immune disfunctions
JP4055015A JPH05124978A (ja) 1991-03-15 1992-03-13 免疫不全との関連を有する退行性病変におけるホスフアチジルセリンおよびその誘導体の使用
KR1019920004186A KR920017659A (ko) 1991-03-15 1992-03-14 면역 이상작용과 관련된 변성 병변에서 포스파티딜세린 및 이의 유도체의 용도

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITPD910055A IT1247165B (it) 1991-03-15 1991-03-15 Uso terapeutico della fosfatidilserina e derivati in patologie degenerative anche associate a disfunsioni immunitarie.

Publications (3)

Publication Number Publication Date
ITPD910055A0 ITPD910055A0 (it) 1991-03-15
ITPD910055A1 ITPD910055A1 (it) 1992-09-15
IT1247165B true IT1247165B (it) 1994-12-12

Family

ID=11389504

Family Applications (1)

Application Number Title Priority Date Filing Date
ITPD910055A IT1247165B (it) 1991-03-15 1991-03-15 Uso terapeutico della fosfatidilserina e derivati in patologie degenerative anche associate a disfunsioni immunitarie.

Country Status (5)

Country Link
EP (1) EP0505817A1 (it)
JP (1) JPH05124978A (it)
KR (1) KR920017659A (it)
CA (1) CA2063039A1 (it)
IT (1) IT1247165B (it)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9203039D0 (en) * 1992-02-13 1992-03-25 Univ London Treatment
AU3333695A (en) * 1994-05-31 1995-12-21 David P. Franklin Methods and products for the control of pathogenic bacteria
US7262167B2 (en) 1995-11-06 2007-08-28 Exibona Ltd. Drug, in particular for modulating the immunological response for the control of viruses, tumors, bacteria and parasites
US6165997A (en) * 1997-11-20 2000-12-26 Statens Serum Institut Phospholipids having antimicrobial activity with or without the presence of antimicrobials
GB9919131D0 (en) * 1999-08-14 1999-10-13 Depuy Int Ltd Joint lubrication
EP1292288B1 (en) * 2000-06-23 2004-09-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem 2-arachidonylglycerol (2-ag) - an inhibitor of tumor necrosis factor -alfa and neuroprotector of brain in closed head injury
TWI281407B (en) 2000-09-18 2007-05-21 Vasogen Ireland Ltd Apoptosis-mimicking synthetic entities and use thereof in medical treatment
CA2319928A1 (en) * 2000-09-18 2002-03-18 Vasogen Ireland Limited Apoptosis-mimicking synthetic entities and use thereof in medical treatments
EP1425020A4 (en) * 2001-08-20 2005-05-18 Tatton Technologies Llc METHOD AND COMPOSITIONS FOR TREATING APOPTOSIS-RELATED DISEASES
KR20060066624A (ko) * 2004-10-20 2006-06-16 주식회사 두산 포스파티딜세린을 함유하는 피부 보호 및 개선용 또는 피부장벽 기능 강화용 조성물
GB0425932D0 (en) * 2004-11-25 2004-12-29 Btg Int Ltd Structured phospholipids
JP5140824B2 (ja) * 2006-04-19 2013-02-13 国立大学法人 東京大学 リゾホスファチジルスレオニンおよびその誘導体
IL182372A0 (en) * 2007-04-01 2008-01-20 Enzymotec Ltd Compositions containing phosphatidylserine in treating diabetes-associated conditions
JP2010184867A (ja) * 2009-02-10 2010-08-26 Univ Of Tokyo リゾホスファチジルスレオニン誘導体
JP2014157014A (ja) * 2011-05-19 2014-08-28 Tohoku Univ 自己免疫疾患治療薬のスクリーニング方法
US20160317560A1 (en) * 2013-11-07 2016-11-03 The University Of North Carolina At Chapel Hill Particles containing phospholipids or bioactive fatty acids and uses thereof
CN110985903B (zh) 2019-12-31 2020-08-14 江苏舒适照明有限公司 一种灯模组
JP2023149482A (ja) * 2022-03-31 2023-10-13 雪印メグミルク株式会社 中枢神経炎症抑制組成物及び組成物を含む飲食品、医薬品、飼料
WO2025009518A1 (ja) * 2023-07-04 2025-01-09 国立大学法人大阪大学 悪液質の予防または改善剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1212900B (it) * 1983-11-17 1989-11-30 Valle Francesco Della Uso terapeutico della fosfatidilserina in malattie del sistema nervoso centrale senza effetti sulla coagulazione sanguigna
US5403592A (en) * 1987-08-25 1995-04-04 Macnaught Pty Limited Lubricant composition for rheumatism

Also Published As

Publication number Publication date
EP0505817A1 (en) 1992-09-30
ITPD910055A0 (it) 1991-03-15
JPH05124978A (ja) 1993-05-21
KR920017659A (ko) 1992-10-21
CA2063039A1 (en) 1992-09-16
ITPD910055A1 (it) 1992-09-15

Similar Documents

Publication Publication Date Title
IT1261949B (it) Composizione terapeutica a base di interferone umano, impiego di interferone umano in tale composizione e relativo metodo.
EP1941904A3 (en) Anti-TNF antibodies and methotrexate in the treatment of autoimmune diseases
NZ299340A (en) Use of tricyclic benzazepines such as vasopressin to treat congestive heart failure and renal disease
HRP950052B1 (en) Use of anti-tnf antibodies as drugs in treating diseases involving elevated interleukin-6 serum levels
NZ271756A (en) Human macrophage inflammatory proteins and coding sequences, their production and use
MY111201A (en) New imidazopyridines
DE69433790T2 (de) Isolierte peptide, die mit mhc mulekül hla-c-klon 10 komplexe bilden und ihre verwendungen
ES2133322T3 (es) Utilizacion de la proteina l2 para el tratamiento terapeutico de los tumores o lesiones causadas por el papilomavirus.
DK0939121T4 (da) TNF-bindende proteiner
ATE258444T1 (de) Therapeutische chemokine rezeptor antagonisten
GB9204015D0 (en) Therapeutic nucleosides
EA199700117A1 (ru) Трициклические бензазепиновые антагонисты вазопрессина, способ их получения, фармацевтическая композиция и способ лечения млекопитающих с использованием трициклических бензазепинов
ES2154741T3 (es) Uso de agentes de union a cd23 en el tratamiento de enfermedades autoinmunes.
ES2153862T3 (es) Bisulfan de administracion parenteral para el tratamiento de enfermedades malignas.
DE69231274D1 (de) Hyperkinetische bewegungsstörung modulierender opiatrezeptor-antagonist
ES2058191T3 (es) Acidos 2-fenil-4-quinolincarboxilicos substituidos.
GEP20033081B (en) Pharmaceutical Agents for Treatment of Parkinson's Disease, ADFD and Microadenomas
HU9301918D0 (en) Compounds with antiviral effect
ES2121103T3 (es) Antagonistas de la angiotensina ii para el tratamiento de enfermedades viricas.
MX9708416A (es) Derivados de piperazino como antagonistas de neuroquininas.
MXPA04004826A (es) Antagonista del receptor de quimioquinas y metodos para su uso.
ES2177769T3 (es) Derivado de aminotetralina para la terapia de trastornos cardiovascu lares.
MY142646A (en) Chemokine receptor antagonists and methods of use therefor
GT199700123A (es) Sales dimesilato de los ligandos del neuropeptido y.
ZA929616B (en) Ethanol adducts of 6-sulfonyl-substituted 3-hydroxychromans and their use as inhalants in diseases.

Legal Events

Date Code Title Description
0001 Granted
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19940315